FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average burden									
ı	hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Pace Megan E					V	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								heck all ap Dir	plicable) ector cer (give title		10% Ow Other (s below)	ner		
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 02/05/2014									√P, Corp. (Comm	,			
50 NORTHERN AVENUE						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) BOSTON MA 02210															Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																	
		Tab	le I - No	n-Deri	vativ	e Se	curities	s Acc	quired, I	Dis	posed c	f, or Be	neficia	lly Own	ed					
1. Title of Security (Instr. 3) 2. Transa Date (Month/Date)					Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (Disposed Of (D) (Instr. 5)				d Secu Bene Own	ficially ed Following	Forn (D) o	rm: Direct) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership					
									Code	v	Amount	(A) or (D)		Tran	eported ansaction(s) nstr. 3 and 4)			(Instr. 4)		
Common Stock 02/05/						2014		A		14,250	14,250 ⁽¹⁾ A S		01	24,350		D				
		-	Гable II -						ired, Di option					y Owne	d					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	Code (In:				6. Date Exe Expiration (Month/Day	Date		of Securi Underlyir	ng e Security	Derivati Securit	derivativ Securitie	e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)		
					Code	v	(A)		Date Exercisabl		Expiration Date	Title	Amount or Number of Shares							
Employee Stock Option (right to	\$77.31	02/05/2014			A		55,000		(2)	O	2/04/2024	Common Stock	55,000	\$0.00	55,00	00	D			

Explanation of Responses:

1. Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2018, subject to (i) acceleration of 50% of shares upon (a) reaching a specified net product sales level over a one-year period for a combination regimen that includes ivacaftor and a CFTR corrector or (b) dosing of the first patient in the first clinical trial to evaluate a second-generation CFTR corrector compound and (ii) acceleration of 50% of shares upon (a) dosing of the first patient in a pivotal trial for a regimen including VX-661 or a specified cancer compound or (b) reaching a specified net product sales level over a one-year period for all our products.

2. The option vests in 16 quarterly installments from 02/05/2014.

Remarks:

Kenneth L. Horton, Attorney-

02/07/2014

In-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.